Ribonucleic acid interference (RNAi) is a relatively new process by which the synthesis of a particular protein can theoretically be completely halted over a controllable temporary time frame. This is done by using small interfering RNA molecules that cause strands of messenger RNA to be disassembled before they can be translated into protein, mimicking a recently discovered system that is used natively by the human body when protein synthesis needs to be immediately halted. This research aims to look at the viability of this method in clinical applications such as cancer treatment and pharmaceutical design by looking at limitations that may be associated with it in its current form, emphasizing how to effectively deliver the molecules necessary to induce RNAi to the interior of cells producing the protein that is intended to be inhibited when RNA strands cannot cross cell membranes and are unstable in the bloodstream.